Reduced-intensity conditioning that harnesses the potential of a graft-versus-tumor (GVT) effect has been proposed as an alternative to conventional myeloablative allogeneic stem cell transplantation. The primary aim is engraftment and this can be achieved with minimal immunosuppression. In this report, we describe the use of such regimens for CML in 17 patients who received human leukocyte antigen (HLA)-matched sibling allografts. Conditioning was with fludarabine, antithymocyte globulin (ATG) and busulfan for the first 11 patients, whereas fludarabine, busulfan and TBI were used for the remaining six patients. Engraftment was prompt in most of the cases. Complications and need for supportive therapy in the immediate post-transplant period were reduced drastically. Only two patients (both in the TBI group) died within the first 100 days. Acute graft-versushost disease (GVHD) grade II-IV was seen in seven patients. Complications occurred later on. Chronic GVHD was observed in 11/17 patients. Lung infection and GVHD were the major killers. In surviving patients, after a median follow-up of 30 months (range 37-21 months), 6/17 (35.3%) are alive. Five are disease free and one patient is still in relapse even after a second donor lymphocyte infusion. Total treatment time and cost were more than with conventional transplants. We conclude that reduced-intensity transplantation still requires further refinement. Bone Marrow Transplantation (2003) 32, 125-129. doi:10.1038/sj.bmt.1704107 Keywords: reduced intensity conditioning regimen; graftversus-host disease; immunosuppression Allogeneic stem cell transplantation (SCT) is offered as a curative option for various hematological and nonhematological malignancies. The conventional approach is associated with a high degree of mortality and morbidity. Patients who are young and without other organ dysfunctions are usually eligible. Attempts to improve results by modifying myeloablative preparations have not documented the superiority of any regimen.
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Allogeneic stem cell transplantation (SCT) is offered as a curative option for various hematological and nonhematological malignancies. The conventional approach is associated with a high degree of mortality and morbidity. Patients who are young and without other organ dysfunctions are usually eligible. Attempts to improve results by modifying myeloablative preparations have not documented the superiority of any regimen. 1 It is now known that the major therapeutic benefit of allogeneic SCT is derived from a graft-versus-tumor (GVT) effect of the transplanted donor cells. 2 In order to harness the potential of GVT, investigators have identified alternatives to the conventional myeloablative approach. Using minimal chemoradiotherapy and primarily immunosuppression, protocols were developed to facilitate a chimeric platform in the host, after donor stem cell engraftment. This chimeric foundation formed the basis for an effective GVT effect. In the event of a relapse, donor lymphocyte infusion (DLI) proved effective. 3 The Jerusalem, 4 Seattle 5, 6 and Texas 7 transplant study groups reported major benefits. These included a significantly reduced incidence of transplant-related complications, allogeneic transplants in otherwise ineligible patients, reduced supportive care and ease of administration and reduced hospitalization.
Prompted by our long-standing observations and by many encouraging reports in the literature, we engaged in a prospective study to evaluate the response to less intensive stem cell transplantation (LIST) in patients suffering from CML. The mainstay was to use minimal chemoradiotherapy and short-term immunosuppression to allow engraftment and a chimeric state for an effective GVL effect. For the first 11 patents, the protocol proposed by Slavin 4 was used. The subsequent six patients received a low-dose total body irradiation (TBI) of 200 cGy-based conditioning, which was a modification of the regimen advocated by the Seattle group. 5, 6 The objective was to assess early mortality and requirement for supportive care, survival and cost of treatment.
Patients and methods
In all, 17 patients suffering from chronic phase CML and eligible for conventional SCT were offered LIST. Informed consent was obtained from all patients after thoroughly explaining the benefits and risks associated with both myeloablative and nonmyeloablative transplant regimens. The Karnofsky performance score (KPS) was more than 80 in all patients. These patients received transplants from December 1998 through October 2000. Patient and donor characteristics are shown in Table 1 . All donors were HLA-matched siblings. Human leukocyte antigen (HLA) typing, for class I and class II antigens, was carried out serologically in most cases. Molecular typing was available for two patients.
The treatment protocols used are shown in Table 2 . In the absence of any graft-versus-host disease (GVHD), cyclosporine was tapered from day +60 onwards and was withdrawn by day +120. For the first three patients, donor marrow was used as the stem cell source. For the other 14, G-CSF mobilized PBSC were used. The two groups of patients received slightly different forms of reducedintensity conditioning. The change was made in an attempt to avoid the early relapses frequently seen in group I patients and also to avoid the complications associated with the intense immunosuppression created by the fludarabine and ATG combination. Chimerism was assessed by cytogenetic analysis (male/female or Ph status using FISH) and change of blood group in ABO mismatched transplants. Disease response was studied by routine bone marrow examination, cytogenetic analysis and nonquantitative detection of bcr-abl transcripts, starting approximately 30 days after SCT and repeated at regular intervals. Microsatellite analysis was not available. If cytogenetic relapse was suspected in the absence of any GVHD, all immunosuppression was withheld for 4 weeks. If the relapse status persisted, patients received DLI starting with 1 Â 10 7 CD3+ cells/kg. Donor lymphocyte infusion was repeated if necessary. Acute and chronic GVHD were graded according to accepted standards. Kaplan-Meier estimations were used to calculate survival probabilities.
Routine infection screening protocols during the stay in the transplant unit included weekly examination and cultures of blood, stool, urine, nasopharygeal aspirates and skin swabs from catheter exit sites. Cytomegalovirus infection was monitored by weekly assays of IgG status and by PCR examination of blood for viral DNA. Other examinations were undertaken if indicated. Use of a reduced-intensity conditioning regimen M Das et al
Results
Results are summarized in Table 3 . No patient experienced a life-threatening complication during the immediate posttransplant period (Table 4) . Moderate mucositis was easily controlled by local therapy. Herpes infection was usually localized and treated with i.v acyclovir. Patients 1-11 received acyclovir prophylaxis for viral infections. To preempt CMV infection, patients were treated with ganciclovir on the slightest clinical suspicion. Since the CMV infection rate was high in group I patients (5/11), prophylaxis with ganciclovir was given to patients in group II. Despite prophylaxis, 2/6 patients tested positive for CMV. Many of these patients developed severe life-threatening complications often associated with GVHD at a later stage. Early mortality (o100 days) was limited to two patients in group II (UPN 13 on day +49 and UPN 17 on day +53) and none in group I.
Supportive care and hospitalization
Seven patients required total parenteral nutrition during the initial hospital stay. Oral intake was usually maintained. Transfusion requirements were much less as compared to conventional conditioning. During the initial stay in the transplant unit, eight patients did not require any platelet transfusions and three patients did not require any red cell transfusions. An average of 5.9 platelet concentrate units and seven packed cell units were consumed. The average duration of initial hospitalization was 35 days (range 22-63 days).
Hematological recovery
The ANC level did not drop below 0.1 Â 10 9 /l in five patients and the platelet count did not drop below 20 Â 10 9 /l in seven patients. In almost all cases recovery was prompt.
GVHD
Results are shown in Table 3 . Acute GVHD grade II-IV was seen in 7/17 patients who were receiving cyclosporine. Patients 13 and 17 expired before day +60 because of GVHD-related complications. Chronic GVHD was diagnosed in 11/17 patients. In eight patients it was extensive, and seven of these finally succumbed to complications.
Disease relapse
Although cytogenetic remission was seen in most patients by day +30 there was re-emergence in UPN 2, 3, 4 and 6 subsequently ( Table 3) . None of these patients had any evidence of active GVHD during one reappearance of the Philadelphia chromosome. Immunosuppression was withdrawn in UPN 6 (day +66). He later developed limited chronic GVHD and immunosuppression was restarted on day +122. Currently, he is in complete cytogenetic remission. DLI was given to UPN 3 and 4. Patient 3 responded completely, whereas UPN 4 did not respond Table 3 Summary of results Use of a reduced-intensity conditioning regimen M Das et al even after a second DLI. Patient 2 developed a bone marrow failure syndrome by day +230, which was supported by a second transplant. Although he continued to be in remission, he suddenly developed lung complications and within a week died on day +418.
UPN

Unusual complications
Unlike with conventional myeloablative transplants where the course is usually predictable, we encountered many episodes of unusual complications, which were at times dramatic. Lung infections dominated this group of events (Table 3) . Of 17 patients, 10 developed some form of lung infection after they had been discharged. Of these, eight patients died because of pulmonary complications. Very often this was because of a combination of multiple organisms including fungus, CMV and Klebsiella. Cytomegalovirus infection was demonstrable in 7/17 patients. Patients 10, 12 and 13 showed the presence of acid fast bacilli. Besides lungs, major organ involvement was usually associated with GVHD. In UPN 5 and 15, the bilirubin level rose above 40 mg/dl. Patient 10 developed severe intracranial aspergillosis, but she responded to antifungal treatment. Herpes infection in UPN 6 was severe and protracted.
Overall survival and final outcome
After a median follow-up of 30 months (range 21-37 months), 6/17 (35.3%) patients are alive ( Figure 1 ). All living patients are in complete molecular remission except UPN 4.
Discussion
In this study, we report the results of a nonmyeloablative approach to curing CML by allogeneic blood stem cell transplantation. As demonstrated by other studies, it was confirmed that it is possible to eliminate the host hematopoietic stem cells that are responsible for the occurrence of CML. As reported earlier for a series of 27 patients with a follow-up 30.5 months from our centre, with a conventional myeloablative approach the survival is 52% with an early mortality rate of 37%. 8 Many of the complications associated with a conventional myeloablative approach could be eliminated and early transplant related mortality was reduced. Although initial engraftment was very successful, the final outcome is disappointing. Only 6/17 (35.3%) patients are alive in this series. This can be attributed to various reasons. First, HLA typing was performed using serological techniques. Serological typing may not identify several antigenic epitopes. This difference has a direct bearing on donor cytotoxic T-cell precursors. The frequency of these precursors has been shown to correlate with survival and development of GVHD. 9 Moreover, CMV seropositive patients with a higher frequency of these precursors are more likely to develop treatment failure because of relapse or death. Recently, our center has been equipped to perform molecular typing for all recipient/donor pairs. Secondly, CMV seropositivity is very high in the Indian population. Seven out of 17 patients had a demonstrable CMV infection. This occurred despite routine prophylaxis with ganciclovir in the group II patients. Treatment of CMV-related complications is very difficult and the mortality is very high. Currently, all patients receiving allogeneic transplants in our center receive CMV prophylaxis with ganciclovir. Thirdly, most of the patients developed lung complications after they were discharged from the protective environment of the transplant unit. This higher frequency is perhaps related to the intense immunosuppression caused by the ATG and fludarabine combination. Opportunistic infections after purine analogue therapy are well recognized 10 and other groups have reported similar observations. 11 Fourthly, the absence of microsatellite assays for chimerism analysis may have hampered our monitoring of the dynamics of chimerism. We have since started using such analysis in all patients. This study has been a major learning experience for our transplant unit. Physicians and the nursing staff have become more alert to complications hitherto not seen or anticipated. Unfortunately, the total treatment time was significantly extended in all patients as compared to conventional transplants. Patients had to report for frequent investigations over a prolonged period of time. As most patients were outstation residents, this had an adverse effect on their social and family life. In almost all the cases the total cost of treatment exceeded the estimated budget. As a result there was severe pressure on the limited Use of a reduced-intensity conditioning regimen M Das et al resources available. Our efforts to slightly intensify the regimen to avoid frequent relapse and to reduce immunosuppression did not meet with much success. Knowledge of experience with similar regimens developed in other centers would be worthwhile.
No other study has highlighted the negative impacts of nonmyeloablative transplants in CML although concern has been expressed in presentations and conferences. We describe the difficulties encountered and we believe this will be of considerable help to centers that have recently initiated or are planning to start such transplants, specially in places with limited resources and infrastructure.
In conclusion, less intensive conditioning is a viable option but requires further fine-tuning to improve results. We recommend that individual patients be evaluated very carefully before offering them this option. Large, cooperative controlled studies will be required to clearly define the benefits and disadvantages to enable customization of treatment.
